Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection.

Archives in cancer research Pub Date : 2016-01-01 Epub Date: 2016-05-27 DOI:10.21767/2254-6081.100071
Jonathan Yun, Fabio M Iwamoto, Adam M Sonabend
{"title":"Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection.","authors":"Jonathan Yun,&nbsp;Fabio M Iwamoto,&nbsp;Adam M Sonabend","doi":"10.21767/2254-6081.100071","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that carry a poor prognosis, with most patients suffering recurrence. Progress has been made in the treatment of this pathology, notably with the widespread use of systemic high dose methotrexate. However, unlike most other malignant CNS neoplasms, surgery for cytoreduction is not routinely performed for this disease, mainly as a result of negative experiences decades ago. Since these studies were published, the availability of intraoperative monitoring, MR imaging and neuro-navigation as well as surgical adjuncts such as fluorescence- guided resection have greatly improved the safety of intracranial procedures. More recent data is suggestive of a potential survival benefit for resection of single PCNSL lesions when patients are subsequently treated with modern regimen high-dose methotrexate, yet this evidence is limited, and should be interpreted conservatively.</p><p><strong>Methods and findings: </strong>A systematic review of the literature was performed to identify trials evaluating surgical options for the treatment of PCNSL.</p><p><strong>Conclusion: </strong>In this review, we provide a critical overview of the evidence favoring and discouraging resection for PCNSL. This literature suffers from several biases and limitations that must be considered in the context of the extrapolation of this literature into clinical decision-making.</p>","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"4 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100071","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives in cancer research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21767/2254-6081.100071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/5/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Background: Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that carry a poor prognosis, with most patients suffering recurrence. Progress has been made in the treatment of this pathology, notably with the widespread use of systemic high dose methotrexate. However, unlike most other malignant CNS neoplasms, surgery for cytoreduction is not routinely performed for this disease, mainly as a result of negative experiences decades ago. Since these studies were published, the availability of intraoperative monitoring, MR imaging and neuro-navigation as well as surgical adjuncts such as fluorescence- guided resection have greatly improved the safety of intracranial procedures. More recent data is suggestive of a potential survival benefit for resection of single PCNSL lesions when patients are subsequently treated with modern regimen high-dose methotrexate, yet this evidence is limited, and should be interpreted conservatively.

Methods and findings: A systematic review of the literature was performed to identify trials evaluating surgical options for the treatment of PCNSL.

Conclusion: In this review, we provide a critical overview of the evidence favoring and discouraging resection for PCNSL. This literature suffers from several biases and limitations that must be considered in the context of the extrapolation of this literature into clinical decision-making.

Abstract Image

Abstract Image

Abstract Image

原发性中枢神经系统淋巴瘤:手术切除作用的重要回顾。
背景:原发性中枢神经系统淋巴瘤(PCNSL)是一种少见的中枢神经系统肿瘤,预后较差,多数患者复发。这种病理的治疗已取得进展,特别是全身大剂量甲氨蝶呤的广泛使用。然而,与大多数其他恶性中枢神经系统肿瘤不同的是,由于几十年前的负面经历,这种疾病通常不进行细胞减少手术。自从这些研究发表以来,术中监测、MR成像和神经导航以及手术辅助如荧光引导切除的可用性大大提高了颅内手术的安全性。最近的数据提示,当患者随后接受现代方案高剂量甲氨蝶呤治疗时,切除单个PCNSL病变可能会改善生存,但这一证据有限,应保守解释。方法和发现:对文献进行了系统的回顾,以确定评估PCNSL治疗的手术选择的试验。结论:在这篇综述中,我们提供了支持和反对切除PCNSL的证据的关键概述。这些文献存在一些偏差和局限性,必须在将这些文献外推到临床决策的背景下加以考虑。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信